LIMBER

LEADING IN MPNs

BEYOND RUXOLITINIB.

Learn about ongoing clinical trials evaluating strategies to improve and expand treatments for patients with myeloproliferative neoplasms (MPNs), such as myelofibrosis (MF)

incyte-limber-about

ABOUT LIMBER

Incyte is a leader in the discovery and development of therapies for patients with MPNs. Despite the breakthrough advances brought by Incyte to patients with MPNs, a significant need for additional treatments still remains for those who have an inadequate response to or are unable to tolerate current therapies. The Leadership In MPNs BEyond Ruxolitinib (LIMBER) program is designed to evaluate multiple monotherapy and combination investigational strategies for patients with MPNs. The program currently has three key areas of focus: development of a new, once-daily formulation of ruxolitinib; ruxolitinib-based combinations with new targets such as PI3Kδ, BET and ALK2; and new therapeutic options. Two pivotal Phase 3 trials were recently initiated to evaluate the safety and efficacy of combination treatment with parsaclisib plus ruxolitinib in MF patients as first-line therapy (LIMBER-313) and in those who have had an inadequate or suboptimal response to ruxolitinib monotherapy (LIMBER-304). In addition, several other Phase 2 trials are ongoing to evaluate efficacy and safety of INCB57643 (BET) in patients with refractory MF; INCB00928 (ALK2) as monotherapy or in combi...

Read More

EXPLORE OUR LIMBER TRIALS

LIMBER | 104

Anemia, Myelofibrosis(MF), Polycythemia Vera (PV)
Recruitment Complete
Learn More

LIMBER | 103

Myelofibrosis(MF), Myelodysplastic Syndromes (MDS)
Recruiting
Learn More
incyte-limber-faq

MYELOFIBROSIS (MF)

WHAT IS MF?
Open

MF is a rare, chronic blood cancer. It can "progress," or get worse, over time. For example, new symptoms may appear or existing symptoms may get worse.1 MF is part of a group of diseases called "myeloproliferative neoplasms," or MPNs. Healthcare professionals sometimes call this condition a bone marrow cancer or blood cancer. Bone marrow is a spongy tissue inside of the bone, and is the primary place where blood cells are made. People with MF have a defect in their bone marrow that results in an abnormal production of blood cells, causing scar tissue to form. 2 MF can result from a progression of other bone marrow diseases or it can occur on its own.3

WHAT ARE COMMON MF SYMPTOMS?
Open

MF can cause the spleen to become quite large. The spleen is a crescent shaped organ that is normally located just under rib cage on the left side. With MF, the spleen can extend below your rib cage, sometimes as much as 8 to 10 inches (20 to 25 cm). Symptoms of an enlarged spleen can include pain or discomfort in the abdomen or under the left ribs, and feeling full when you have not eaten or have eaten very little.4,5,6 In addition to the symptoms caused by an enlarged spleen, MF can affect the body in other ways, including fatigue, itching, night sweats, fever, unexplained weight loss, bone pain, and bruising or bleeding easily.7,8,9

WHAT CAUSES MF?
Open

MF is complex and may have many contributing factors. Scientists think that it may be related to changes in certain genes. These changes are called "mutations."7 People with MF have bone marrow that does not work correctly. In some people with this condition, mutations may affect the behavior of certain proteins, and cause the bone marrow to make too many or too few blood cells. This imbalance of blood cells may cause some of the symptoms of MF.7 This often happens even if mutations are not present.10 Another cause of symptoms may be the overproduction of certain proteins called "cytokines." Cytokines can cause inflammation. When your body has too many cytokines, you may experience itching, night sweats, and some other symptoms of MF.7,8,10

REFERENCES

  1. LLS MF Facts, Mayo Clinic MF
  2. LLS MF Facts, Mayo Clinic MF, MPN Foundation
  3. LLS Fact Sheet
  4. Benter, 2011
  5. Chapman, 2020
  6. Mayo Clinic, Enlarged Spleen, 2012
  7. LLS MF Facts
  8. Verstovsek, CanRes, 2010
  9. Emmanuel, JCO, 2012
  10. Dorland
  11. Boissinot 2010

JOIN THE INCYTE COMMUNITY

Innovating for Tomorrow

Join the Incyte Community to receive updates on news about Incyte, including information on newly enrolling trials. The Incyte Community enables you to stay informed & prepared to contribute to research you care about. Please review the Privacy Policy to understand how your information will be collected and processed. If you provide information about another person, by providing that information you certify that you have their authorization to share their personal information.  

Join us in our journey as we continue to Solve On.

1/3

Participant Information

Please fill in the form below if you would like to stay in touch regarding ongoing and newly enrolling trials.

Fields marked with asterisk (*) are mandatory.

Innovating for tomorrow